What They Build
Eyestem develops cell-therapy products for retinal degeneration, using stem-cell-derived retinal pigment epithelial cells and related ophthalmology platforms.
Why They Matter
Cell therapy is frontier work because the product is biology, manufacturing process, and clinical evidence at once. Eyestem matters as an Indian company pursuing original regenerative therapies in a disease area with large unmet need. The challenge is clinical proof and manufacturing consistency.
Founders
Jogin Desai, Rajani Battu, Dileep Dhanak
Recent Milestones
- Retinal cell therapy program advanced
- Clinical development plans disclosed
- Institutional funding announced